newsfilter
← Latest News
GlobeNewswire·

PharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB:PHRRF) (CSE:PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine,